Figure 1.

Three-pronged approach to improve chimeric antigen receptor (CAR) T cell therapies in solid tumors. A multi-faceted attack on solid tumors resistant to standard CAR T cell therapies may best augment their efficacy in clinical trials. The ultimate CAR T cell therapy should encompass three axes: (1) a CAR with high fidelity targeting of more than one tumor antigen and trafficking capacity, (2) selection of a T cell subset with potent self-renewal and migratory capacity for long-term persistence and immunity, and (3) ability to harness and rejuvenate the host response to tumor neoantigens. A single arm (CAR, subset, or host response) has not been sufficient for long-term responses against aggressive solid tumors to date.